Navigation Links
Tailoring glioblastoma therapies: 1 size does not fit all

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Dr. Bonni's group found that the transcription factor STAT3 has either a tumor promoting or tumor suppressive effect depending upon the genetic profile of the glioblastoma tumor.

Glioblastomas are the most common and aggressive type of adult brain cancer, with an annual incidence of approximately 13,000 in the United States, and an expected median survival rate of just over a year. STAT3 is a cytokine-activated transcription factor that has been previously reported to play a pro-oncogenic role in tumor development. Thus, much effort has been aimed at the development of STAT3 inhibitors as chemotherapeutic agents.

Dr. Bonni and colleagues now report that STAT3 can function as either a tumor suppressor or an oncoprotein. Using a mouse model system of two common genetic mutations in glioblastomas - PTEN deficiency or EGFRvIII activation -- the researchers show that PTEN regulates STAT3 tumor suppressor function, while STAT3 cooperates with the EGFRvIII oncoprotein to promote tumor growth.

Thus, the researchers convincingly demonstrate a need for effective therapies tailored to the unique genetic thumbprint of individual glioblastoma tumors. "These findings may change the way we approach not only glioblastoma but other types of cancer as well", says Azad Bonni, senior author of the study.


Contact: Heather Cosel
Cold Spring Harbor Laboratory

Page: 1

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
Post Your Comments:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: